Search Results for “medical devices” – Page 51 – media

VR Can Alleviate Brain Tumor Patients’ Anxiety During Treatment, Study Finds

AppliedVR teamed up with the National Cancer Institute to study the feasibility of VR to alleviate anxiety in brain tumor patients undergoing imaging scans. The research partners recently announced interim analysis results from their clinical study — they said that not only would VR intervention be a feasible option to reduce patients’ anxiety, but that patients would report high satisfaction levels as well. Patients diagnosed with brain tumors experience notably higher levels of significant distress compared to other solid tumor patients. This heightened distress can be attributed to the disease’s demanding clinical trajectory, as well as its high symptom burden. On top of these challenges, patients with brain tumors face the additional hardship of undergoing frequent neuroimaging assessments to monitor the progress of their disease, leading to what is often referred to as “scanxiety.” This term refers to the anxiety and stress resulting from the anticipation of these medical scans and their potential ...
- Source: drugdu
- 82
- July 25, 2023
New ultra-flexible neural implant records single-neuron activity in deep-brain regions

A new ultra-small and ultra-flexible electronic neural implant, delivered via blood vessels, can record single-neuron activity deep within the brains of rats, according to new study. “This technology could enable long-term, minimally invasive bioelectronic interfaces with deep-brain regions, writes Brian Timko in a related Perspective. Brain-machine interfaces (BMIs) enable direct electrical communication between the brain and external electronic systems. They allow brain activity to directly control devices such as prostheses or modulate nerve or muscle function, which can help individuals with paralysis or neurological disorders regain function. However, most conventional BMIs are limited to measuring neural activity at the brain’s surface. Recording single-neuron activity from deep brain regions often requires invasive intracranial surgery to implant probes, which can result in infection, inflammation, and damage to brain tissues. An alternative approach to implanting bioprobes into deep-brain regions is via the brain’s vascular network. Here, Anqi Zhang and colleagues present ultra-flexible micro-endovascular ...
- Source: drugdu
- 106
- July 22, 2023
Black Patients with ICDs Have Higher Rate of Post-Implant Cardiac Events and Risk of Death

Black patients with implantable cardioverter defibrillators (ICDs) have a significantly higher burden of disease than white patients with the same device, according to a new study from University of Rochester Medical Center (URMC) cardiology researchers. Analyzing data from clinical trials conducted over a 20-year period by the Clinical Cardiovascular Research Center (CCRC) at URMC, investigators concluded that not only did Black patients with ICDs tend to be significantly younger than white patients, but they also had a higher rate of post-implant cardiac events and risk of death. When a patient is at risk for cardiac arrest, an ICD helps to monitor their heart rhythm, and if an abnormality is detected, the device delivers a shock of electricity to reset the heartbeat to a normal rhythm. The study, published in Circulation, examines the rate of events that a patient experiences after their ICD is implanted. After three years of ...
- Source: drugdu
- 127
- July 19, 2023
What the New CMS Payment Proposals Mean for Device Makers

Dive Brief The Centers for Medicare and Medicaid Services shared a pair of proposed rules on Thursday afternoon that set rates for physician payments and outpatient procedures. The agency issued the 2024 Hospital Outpatient Prospective Payment System and 2024 Physician Fee Schedule proposed rules, both of which are expected to be finalized this fall. Glaukos could be the biggest beneficiary of the proposals among device makers, with an increase in outpatient facility fee rates likely to provide a “meaningful boost” for its iStent device to treat patients with glaucoma, BTIG analyst Ryan Zimmerman wrote in a research note on Thursday. Dive Insight The two payment proposals include reimbursement increases for some medical device companies, and cuts for others. San Clemente, Calif.-based ophthalmic device company Glaukos is among those who stand to benefit. Its ambulatory surgical center facility fee for the iStent infinite device was nearly doubled ...
- Source: drugdu
- 134
- July 17, 2023
FTC intervenes to correct Medtronic’s ‘erroneous assertions’ in antitrust case

Dive Brief The Federal Trade Commission has intervened in a legal case to correct what it called “erroneous assertions and mistaken legal points” made by Medtronic. In an amicus brief filed Monday, the FTC rebuts aspects of Medtronic’s defense against accusations made by Applied Medical Resources in an antitrust case. The FTC has taken no position on the accuracy of the allegations but filed the brief because it said Medtronic made “wrong” arguments with “broad implications for antitrust enforcement” in its filing to dismiss Applied’s claims. Dive Insight Applied Medical filed a lawsuit against Medtronic earlier this year. The manufacturer of bipolar energy devices accused Medtronic of conspiring to bundle devices for cutting tissue and sealing vessels “in a way that is unhealthy for competition, hospitals, and patients in need of medical treatment.” Medtronic called the claims “baseless” and moved to dismiss the case. The argument for dismissing the case ...
- Source: drugdu
- 115
- July 8, 2023
Teleflex recall of separating vascular catheters labeled Class I event

Dive Brief Teleflex’s recall of its Arrow Endurance Extended Dwell Peripheral Catheter System was categorized by the U.S. Food and Drug Administration as a Class I event, the most severe type of recall. The company began the recall in May after receiving 83 complaints, including 18 reports of injuries. If the catheter separates while in a blood vessel, fragments could spread to other parts of the body and cause adverse events including heart attack and death, the FDA said in a notice. Hospitals should check if they have any of the 262,016 devices recalled in the U.S. and stop using the affected products. Teleflex is asking clinical staff overseeing patients who are currently using an affected product to weigh the risks and benefits of removing and replacing the device. Dive Insight Teleflex acquired Arrow International in 2007 to gain control of a portfolio of vascular access devices. That portfolio now ...
- Source: drugdu
- 136
- June 30, 2023
More than 1.31 billion people could have diabetes by 2050, study says

Dive Brief More than 1.31 billion people worldwide could be living with diabetes by 2050, according to estimates published in the Lancet. In 2021, roughly 529 million people worldwide had diabetes, according to the International Diabetes Federation. The rise in prevalence is expected to be driven by increases in Type 2 diabetes. Overall healthcare spending related to diabetes is expected to rise to $1.054 trillion by 2045, the authors wrote. Global spending in 2021 was estimated at $966 billion by the International Diabetes Federation. Dive Insight With diabetes cases expected to increase globally, current treatment is focused on biomedical interventions and new devices, according to an editorial published in the Lancet that accompanied the researchers’ findings. The authors said people who are marginalized and discriminated against suffer the “most and worst consequences” of diabetes, and “addressing structural racism must become a core component of preventive strategies and health promotion — ...
- Source: drugdu
- 113
- June 28, 2023
Novo Nordisk says in talks to acquire French device-maker Biocorp for $165M

Dive Brief Novo Nordisk said it is in exclusive talks to buy French medical device company Biocorp. Novo Nordisk will buy out Biocorp’s main shareholder, Bio Jag, for 35 euros per share, and then make a tender offer for any outstanding shares at the same price, the companies said Monday. The offer would value all of the company at 154 million euros ($165 million). Denmark-based Novo Nordisk, which makes pharmaceutical products and insulin pens, has been collaborating with Biocorp since 2021 on a smart pen cap that tracks information on dose, date and time of injection. Dive Insight Novo Nordisk wants to innovate faster and develop new connected devices, and expects that Biocorp would complement its internal efforts, said Marianne Ølholm, Novo Nordisk’s senior vice president of devices and delivery solutions. Novo Nordisk will work with Biocorp to invest in new devices and drug delivery solutions for people with chronic ...
- Source: drugdu
- 130
- June 8, 2023
Restoring thought-controlled movement after spinal cord injury using a brain-computer interface

ONWARD Medical N.V., the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces a publication in Nature showing that a wireless brain-computer interface (BCI) can use thought to modulate ARC Therapy. Researchers reported that when paired with ARC Therapy, an implanted BCI allowed an individual to gain augmented control over when and how he moved his paralyzed legs. Dave Marver (CEO of ONWARD) said, “This publication shows the remarkable potential of ARC Therapy to be enhanced with the introduction of a BCI, facilitating more natural movement based on the thoughts of a person living with paralysis. We have positioned ONWARD as a leader in the BCI field with our unique understanding of spinal cord stimulation for people with SCI.” As a neuroscientist and professor, EPFL, and Co-author of the Nature Paper, Grégoire Courtine said, “The ...
- Source: drugdu
- 127
- May 30, 2023
Abbott wins FDA spinal cord stimulation approval to challenge Nevro for back pain market

Dive Brief The U.S. Food and Drug Administration has approved Abbott’s spinal cord stimulation devices for the treatment of non-surgical back pain. Abbott landed the label expansion after showing its BurstDR spinal cord stimulation technology improved outcomes more than conventional medical management in people with chronic back pain who were ineligible for surgery. The label expansion comes 16 months after Nevro won FDA approval in non-surgical refractory back pain and four months after Boston Scientific released data on its rival device in the setting. Dive Insight: Abbott competes with Boston Scientific, Medtronic and Nevro for the spinal cord stimulation market and the four players are continually looking to expand into new areas where they are free from the intense competition that characterizes the core indications. Nevro unlocked an opportunity early last year, when it said it was the only company with specific labeling to treat non-surgical refractory back pain. Now, ...
- Source: drugdu
- 134
- May 20, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.